PRESS RELEASE published on 04/01/2026 at 18:00, 6 months 1 day ago AMÉLIORER LE TAUX DE SUCCÈS DES ESSAIS CLINIQUES : UN ENJEU STRUCTURANT POUR LA RetD PHARMACEUTIQUE AU COEUR DE LA STRATÉGIE DU GROUPE ATON Le Groupe Aton se concentre sur l'avant-clinique intelligent pour améliorer la prédictivité des décisions en R&D pharmaceutique et réduire le risque clinique. Prochaine publication sur Bcell Design et résultats annuels le 28 avril 2026 R&D Pharmaceutique Aton Avant-clinique Intelligent Risque Clinique Bcell Design
BRIEF published on 03/11/2026 at 18:35, 6 months 22 days ago Inoviem Scientific Advances Développement de médicaments avec une approche centrée sur le patient Médecine Personnalisée Innovation Pharmaceutique Inoviem Scientifique Développement De Médicaments Centré Sur Le Patient Programmes Précliniques
BRIEF published on 03/11/2026 at 18:35, 6 months 22 days ago Inoviem Scientific Advances Drug Development with Patient-Centric Approach Personalized Medicine Pharmaceutical Innovation Inoviem Scientific Patient-centric Drug Development Preclinical Programs
PRESS RELEASE published on 03/11/2026 at 18:30, 6 months 22 days ago ATON: UPDATE ON THE ACTIVITIES OF ITS SUBSIDIARY INOVIEM SCIENTIFIC Aton Group's subsidiary, Inoviem Scientific, transforms drug development by prioritizing patient samples & AI technology, accelerating preclinical programs with high-value translational data AI Technology Drug Development Inoviem Scientific Aton Group Patient Sample
BRIEF published on 03/11/2026 at 18:20, 6 months 22 days ago Inoviem Scientific: Advances in Pharmaceutical Development Personalized Medicine Pharmaceutical Development Translational Pharmacology Inoviem Scientific Integrated Platform
BRIEF published on 03/11/2026 at 18:20, 6 months 22 days ago Inoviem Scientific : Avancées dans le Développement Pharmaceutique Médecine Personnalisée Développement Pharmaceutique Pharmacologie Translationnelle Inoviem Scientific Plateforme Intégrée
PRESS RELEASE published on 03/11/2026 at 18:15, 6 months 22 days ago ATON : POINT D'AVANCEMENT SUR L'ACTIVITÉ DE LA FILIALE INOVIEM SCIENTIFIC Le Groupe Aton via sa filiale Inoviem Scientific innove dans le développement de médicaments en utilisant des échantillons de patients pour des analyses moléculaires assistées par IA Médecine Personnalisée Développement Pharmaceutique Groupe Aton Innovation Thérapeutique Inoviem Scientific
BRIEF published on 02/18/2026 at 18:35, 7 months 12 days ago Hadrien Lanvin Appointed Deputy CEO of Aton Group Biotechnology Strategic Growth Deputy CEO Hadrien Lanvin Aton Group
BRIEF published on 02/18/2026 at 18:35, 7 months 12 days ago Hadrien Lanvin appointed Deputy Managing Director of the Aton Group Biotechnology Life Sciences Appointment Hadrien Lanvin Aton Group
BRIEF published on 02/18/2026 at 18:35, 7 months 12 days ago Hadrien Lanvin nommé directeur général adjoint du groupe Aton Biotechnologie Croissance Stratégique Directeur Général Adjoint Groupe Aton Hadrien Lanvin
Published on 10/02/2026 at 13:50, 6 hours 4 minutes ago AI/ML Innovations Appoints Lynn Chapman as Chief Financial Officer and Announces Share Issuance for Debt Settlement
Published on 10/02/2026 at 13:00, 6 hours 54 minutes ago Evergold Drills 4.9 m of 7.70 g/t Au and 186.0 g/t Ag Within 13.5 Metres of 2.84 g/t Au and 127.6 g/t Ag in First 2026 Drill Holes at Golden Lion
Published on 10/02/2026 at 13:00, 6 hours 54 minutes ago Alaska Energy Metals Appoints Independent Director, Thomas Benson
Published on 10/02/2026 at 13:00, 6 hours 54 minutes ago Datavault AI CEO to Present "Operating System for Tokenized Assets" at XRP Seoul 2026
Published on 10/02/2026 at 19:46, 7 minutes ago innoscripta SE: Update on the Tax Authorities’ Investigation – Business Operations Continue as Usual – Full Transparency Assured – Invitation to Shareholders for an In-Person Product Presentation
Published on 10/02/2026 at 19:00, 54 minutes ago INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF
Published on 10/02/2026 at 18:00, 1 hour 54 minutes ago EQS-Adhoc: AMUNDI PHYSICAL GOLD ETC (the “ETC”): Release of the first Supplemental Base Prospectus (the “Supplemental”)
Published on 10/02/2026 at 18:00, 1 hour 54 minutes ago AMUNDI PHYSICAL GOLD ETC (the “ETC”): Release of the first Supplemental Base Prospectus (the “Supplemental”)
Published on 10/02/2026 at 18:00, 1 hour 54 minutes ago AMUNDI PHYSICAL GOLD ETC (the “ETC”): Release of the first Supplemental Base Prospectus (the “Supplemental”)
Published on 10/02/2026 at 17:45, 2 hours 9 minutes ago Information concerning the total number of voting rights and shares 2026 09 30
Published on 10/02/2026 at 17:45, 2 hours 9 minutes ago Informations relatives au nombre total de droits de vote et d’actions 2026 09 30
Published on 10/02/2026 at 17:35, 2 hours 19 minutes ago Peugeot Invest - Déclaration du nombre d'actions et de droits de vote
Published on 10/02/2026 at 17:30, 2 hours 24 minutes ago Aéroports de Paris SA - 2027 Financial Calendar
Published on 10/02/2026 at 17:30, 2 hours 24 minutes ago Aéroports de Paris SA - Calendrier financier 2027
